Literature DB >> 15990140

Positron emission tomography in the quantification of cellular and biochemical responses to intrapulmonary particulates.

Hazel A Jones1, Kurt Hamacher, John C Clark, John B Schofield, Thomas Krausz, Christopher Haslett, Alan R Boobis.   

Abstract

Inhaled mineral dusts and fibres can cause chronic pulmonary inflammation, often leading to permanent scarring with loss of function, but the mechanisms involved remain obscure. There are currently no good methods for monitoring inflammatory processes in situ. Positron emission tomography (PET) of suitable intravenously injected radiolabelled markers provides non-invasive and repeatable methods of quantifying biochemical and cellular responses. We have developed animal models of fibrotic and non-fibrotic pulmonary response to particulate instillation and characterised these by histology. Different components of the inflammatory response have been investigated by PET: (1) [(18)F]-labelled fluoro-deoxyglucose, a positron emitting glucose analogue, accumulates in cells in proportion to their glucose uptake; ex vivo microautoradiography indicates that neutrophils are the cells responsible for an increased signal during pulmonary inflammation; a persistently high uptake is associated with lung scarring. (2) The radioligand [(11)C]-R-PK11195 binds to benzodiazepine-like receptors abundant in macrophages; following particulate instillation, the [(11)C]-R-PK11195 PET signal tracks with lung macrophage accumulation and also localises to regions consistent with macrophage clearance; poor macrophage clearance is associated with fibrosis. (3) [(18)F]-fluoroproline is likely a substrate for extracellular matrix production, especially proline-rich collagen; during active scarring, the rate of lung uptake of fluoroproline is elevated. Localisation of radioactivity in the lung has been validated ex vivo by microautoradiography of tritium analogues of each of the positron emitting tracers. The use of PET to monitor different inflammatory processes by repeated scanning of the same animal or individual is helping to identify key events in the fibrotic process.

Entities:  

Mesh:

Year:  2005        PMID: 15990140     DOI: 10.1016/j.taap.2005.02.027

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  6 in total

Review 1.  Noninvasive imaging of experimental lung fibrosis.

Authors:  Yong Zhou; Huaping Chen; Namasivayam Ambalavanan; Gang Liu; Veena B Antony; Qiang Ding; Hrudaya Nath; Janet F Eary; Victor J Thannickal
Journal:  Am J Respir Cell Mol Biol       Date:  2015-07       Impact factor: 6.914

Review 2.  Overview of positron emission tomography in functional imaging of the lungs for diffuse lung diseases.

Authors:  Avanti V Gulhane; Delphine L Chen
Journal:  Br J Radiol       Date:  2021-11-09       Impact factor: 3.629

3.  Quantification of (R)-[11C]PK11195 binding in rheumatoid arthritis.

Authors:  M A Kropholler; R Boellaard; E H Elzinga; C J van der Laken; K Maruyama; R W Kloet; A E Voskuyl; B A C Dijkmans; A A Lammertsma
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-11-29       Impact factor: 9.236

4.  Practical syntheses of 4-fluoroprolines.

Authors:  Mukund S Chorghade; Debendra K Mohapatra; Gokarneswar Sahoo; Mukund K Gurjar; Manish V Mandlecha; Nitin Bhoite; Santosh Moghe; Ronald T Raines
Journal:  J Fluor Chem       Date:  2008-09       Impact factor: 2.050

5.  Use of cis-[18F]fluoro-proline for assessment of exercise-related collagen synthesis in musculoskeletal connective tissue.

Authors:  Dorthe Skovgaard; Andreas Kjaer; Katja Maria Heinemeier; Malene Brandt-Larsen; Jacob Madsen; Michael Kjaer
Journal:  PLoS One       Date:  2011-02-11       Impact factor: 3.240

6.  PET imaging of lung inflammation with [18F]FEDAC, a radioligand for translocator protein (18 kDa).

Authors:  Akiko Hatori; Joji Yui; Tomoteru Yamasaki; Lin Xie; Katsushi Kumata; Masayuki Fujinaga; Yuichiro Yoshida; Masanao Ogawa; Nobuki Nengaki; Kazunori Kawamura; Toshimitsu Fukumura; Ming-Rong Zhang
Journal:  PLoS One       Date:  2012-09-12       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.